Clinuvel Pharmaceuticals (OTCMKTS:CLVLY – Get Free Report) will likely be announcing its resultson Tuesday, September 1st. Analysts expect Clinuvel Pharmaceuticals to announce earnings of $0.3226 per share and revenue of $43.67 million for the quarter.
Clinuvel Pharmaceuticals Stock Performance
Shares of Clinuvel Pharmaceuticals stock opened at $7.35 on Friday. Clinuvel Pharmaceuticals has a 52-week low of $5.98 and a 52-week high of $9.00. The company’s 50 day moving average price is $7.29 and its 200-day moving average price is $7.08.
Clinuvel Pharmaceuticals Company Profile
Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.
The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S.
See Also
- Five stocks we like better than Clinuvel Pharmaceuticals
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Clinuvel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinuvel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
